AmerisourceBergen Corporation

AmerisourceBergen Corporation managed to surpass the revenue and earnings expectations of Wall Street in the last quarter. The company observed continued progress across its businesses in the quarter, producing significant revenue growth. AmerisourceBergen advanced its business by concentrating on 4 main areas: community providers, specialty medicine and services, global access and opportunity, and customer partnerships, all of which were influenced by its pharmaceutical-centric strategy. They used their solid commercial strengths to deliver solutions and build strong connections with clients and partners worldwide. Their investment in OneOncology was a significant milestone in their expanding support for community oncology doctors in the US. This investment further broadens the company’s reach in the oncology sector and enables it to strengthen its existing solid relationships with neighborhood oncologists. In light of the ongoing expansion and change in the oncology landscape, their team looks forward to increasing the value they offer to their partners. Besides, their focus on specialty medicine and services sets them apart from their pharmaceutical manufacturer partners throughout the commercialization process, from clinical development to patient access, as they continue to grow their downstream solutions in the specialty. We give AmerisourceBergen Corporation a ‘Hold’ rating with a revised target price.